Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

Study of the Absolute Bioavailability of BMS-626529 in Healthy Subjects Following Oral Dosing of BMS-663068 and Intravenous Dosing of BMS-626529

A phase I absolute bioavailability study of BMS-626529 following oral and intravenous dosing

Inclusion Criteria:

• Generally healthy
• BMI 18.0-32.0 kg/m2
• Men sexually active with women of childbearing potential must follow instructions for contraception for the duration of treatment plus 90 days
• Men must refrain from sperm donation for the length of the study and for 90 days
• Sign informed consent

Exclusion Criteria:

• Significant medical illness
• Tobacco use in the last 12 months
• Major surgery within 4 weeks of study administration
• Donation of blood within 4 weeks of study administration
• Current or recent (within 3 months of study administration) of gastrointestinal disease